Restructuring
 12 Months Ended
Dec. 31, 2013
Restructuring [Abstract]  
Restructuring
15. Restructuring

In February 2013, the Company adopted a plan to restructure the operations of Emergent Product Development UK Limited ("EPDU") and OETC due to the results of the Phase IIb clinical trial for the Company's tuberculosis vaccine product candidate. The Company completed this restructuring as of June 30, 2013, except for the payment of certain termination benefit obligations that remain payable as of December 31, 2013.


The restructuring plan included a headcount reduction of 14 employees at EPDU, the termination of a facility lease, and the impairment of leasehold improvements and equipment. These costs, which are included in selling, general and administrative expense in the Company's statement of operations and are included within the Biosciences segment, are detailed below:

 
 
Incurred during
 
 
 
the year ended
 
(in thousands)
 
December 31, 2013
 
Termination benefits
 
$
2,114
 
Contract termination costs
  
431
 
Other costs
  
261
 
Total
 
$
2,806
 

The following is a summary of the activity for the liabilities related to the EPDU restructuring:

 
 
  
Contract
  
  
 
 
 
Termination
  
Termination
  
Other
  
 
(in thousands) 
 
Benefits
  
Costs
  
Costs
  
Total
 
Balance at December 31, 2012
 
$
-
   
-
  
$
-
  
$
-
 
Expenses incurred
  
2,114
   
431
   
134
   
2,679
 
Amount paid
  
(1,660
)
  
(431
)
  
(134
)
  
(2,225
)
Other adjustments
  
-
   
-
   
-
   
-
 
Balance at December 31, 2013
 
$
454
  
$
-
   
-
  
$
454